SCHEMBL863647

SCHEMBL863647

CCN(CC)c1nc2c(Cl)cccc2cc1C(C)Nc1ncnc2[nH]cnc12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 16/20 0.50
PIK3CG P48736 7/20 0.38
PIK3R1 P27986 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
ABCB11 O95342 1/20 0.38
TBXA2R P21731 1/20 0.38
HTR2A P28223 1/20 0.38
PDE3A Q14432 1/20 0.38
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
AXL P30530 1/20 0.33
MERTK Q12866 1/20 0.33
AURKA O14965 1/20 0.33
RPS6KB1 P23443 1/20 0.33
AURKB Q96GD4 1/20 0.33
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863646 1.00 PIK3CD (0.50) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL864956 0.84 PIK3CD (0.46) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL864955 0.84 PIK3CD (0.46) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL863372 0.83 PIK3CD (0.54) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL863371 0.83 PIK3CD (0.54) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL863864 0.83 PIK3CD (0.45) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL863847 0.82 PIK3CD (0.34) PIK3CDPIK3CGPIK3CAPIK3CBLMNA
SCHEMBL863846 0.82 PIK3CD (0.34) PIK3CDPIK3CGPIK3CAPIK3CBLMNA
SCHEMBL12004581 0.81 PIK3CD (0.58) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB
SCHEMBL4185196 0.81 PIK3CD (0.58) PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396315-B1 QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-08-31 EP disclosed
US-8513284-B2 Fused pyridine and pyrazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2013-08-20 US disclosed
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA PIK3CD 14/4885PIK3CG 21/4885PIK3R1 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.